Featured Article
Blood-based microRNA (miRNA) tests could diagnose mild cognitive deficits and predict the progression to Alzheimer’s disease years before it manifests clinically, research suggests.
Precision Oncology Today
Magazine
Minimal Disease, Maximum Benefit
As both flow cytometry technology and genomic sequencing have taken technological leaps forward, the sensitivity and specificity of testing has increased to include MRD for solid tumors. Leveraging advances in next-generation sequencing, MRD test developers can look for thousands of disease markers and even detect one cancerous cell among a million healthy cells. This level of sensitivity provides evidence of disease recurrence months before traditional follow-up screening methods.
Immunogenomics is on the Way Up
Combining immune-system science, omics, and various computational algorithms might produce success where advanced cancer treatments have failed.
Trending on Inside Precision Medicine
Black Women Face Higher Risk of Death from All Breast Cancer Types
Researchers from the Mass General Brigham have revealed that Black women face a higher risk of dying from breast cancer than White women across all tumor subtypes.
Certain Diabetes Drugs May Lower Risk of Dementia and Parkinson’s Disease
A recent study from researchers in South Korea contends that certain diabetes medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors may be linked to a reduced risk of developing dementia and Parkinson’s disease.
MicroRNAs Show Potential for Dementia Screening
Blood-based microRNA (miRNA) tests could diagnose mild cognitive deficits and predict the progression to Alzheimer’s disease years before it manifests clinically, research suggests.
